| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_653c418e41edbb4e1ce8bc5e53e70cec |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate |
2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19989569d9acb3998e1dc0cb026a3ed5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91968c1d64d6107a7970acc6dda8be49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29d3aadf6265db43cce51cceb712121d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2167b681b232d56a01aca9e477c6ec83
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd5866452bc6d66f0b8035ae3cec429
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56398b9d52ba5cb061de9443d2981dd2 |
| publicationDate |
2021-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-112760380-A |
| titleOfInvention |
Markers for assessing sensitivity and/or prognosis of triple-negative breast cancer to neoadjuvant chemotherapy drugs and their applications |
| abstract |
The invention provides a marker for evaluating the sensitivity and/or prognosis of triple negative breast cancer to neoadjuvant chemotherapy drugs and its application. The marker for evaluating the sensitivity and/or prognosis of triple-negative breast cancer to neoadjuvant chemotherapy drugs is RAD21 and/or its protein. RAD21 is highly expressed in breast cancer tissues or breast cancer cell lines and is associated with poor prognosis of patients. RAD21 promotes the migration and invasion of triple-negative breast cancer cells. RAD21 is involved in regulating triple-negative breast cancer's response to neoadjuvant chemotherapy drugs doxorubicin, 5- Fluorouracil sensitivity is a potential therapeutic target or a predictor of treatment regimen selection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114002133-A |
| priorityDate |
2021-02-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |